Trials / NCT06592131
BF844 Safety and Pharmacokinetic Study in Healthy Volunteers
Status unknown Phase 1 Drug / neuroprotection
- Sponsor
- EyeXCel Pty. Ltd.
- Treatment
- BF844
- Gene
- Not stated
- Conditions
- Usher Syndrome Type 3
- Ages
- 18 Years to 45 Years
- Enrollment
- 76 participants
- Started
- 2024-09-09
- Main results expected
- 2025-03-06
- Results posted
- Not yet
- Record last updated
- 2024-09-19
What the study is testing
First-in-Human Phase-1 Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Ascending Doses of BF844 when Administered Orally to Healthy Adult Participants.
Where it runs
Australia (1)
- Linear Clinical Research, Perth, Australia